Procter & Gamble Health Ltd (PGHL)

📊 Quarterly Results (₹ Cr)

Revenue growth has decelerated from double-digit levels seen in FY2025-26 (16% growth reported at the AGM) to 7% in Q1 FY2026, while PAT growth, though strong, is increasingly driven by non-recurring items rather than operational expansion. Margins remain stable but show signs of compression in operating performance — OPM declined from 35.1% in September 2025 to 25.7% in June 2026 — despite flat operating expenses, suggesting pricing pressure or input cost headwinds. The absence of new growth levers or capital expenditure plans in recent filings raises questions about the sustainability of current growth trajectories.

🔮 Management Outlook & What's Next

Management has not provided forward-looking guidance in the latest filings, but at the 59th AGM scheduled for September 3, 2026, the company highlighted continued focus on innovation and market leadership, with FY2025-26 financials showing ₹1,385 crores in sales and ₹327 crores in PAT, reflecting 16% sales and 30% PAT growth. The dividend declaration of ₹205/share total underscores confidence in cash flow generation. However, no strategic updates, new product launches, or market expansion plans were detailed in the AGM notice or accompanying report, leaving the long-term outlook reliant on historical performance rather than articulated new initiatives.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet remains exceptionally strong, with equity of ₹17 crores and reserves growing to ₹603 crores as of March 2026, while borrowings remain negligible at ₹6 crores. Total assets rose to ₹894 crores, indicating modest asset base expansion without leverage. This financial profile supports a conservative capital allocation strategy, with no evidence of aggressive reinvestment or debt-funded growth. The company is prioritizing capital efficiency and shareholder returns, as evidenced by consistent dividend payouts and minimal external financing needs.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional investor interest has shown signs of softening: FII holding declined from 7.24% in Q2FY26 to 6.33% in Q1FY27, while DII holdings peaked at 13.84% in Q3FY26 but have since stabilized. Promoter holding remains stable at 51.82%, indicating no dilution or stake sales. The narrowing institutional interest may reflect market caution despite strong fundamentals, possibly due to broader sector headwinds or valuation concerns. The growing number of shareholders (49,056 in Q1FY27) suggests retail participation is increasing, but the lack of institutional accumulation could limit upside momentum.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Revenue growth has slowed to 7% YoY in Q1 FY2026 from 16% in FY2025-26, with no new growth drivers disclosed, raising concerns about market saturation in key segments. 2) Operating performance shows margin compression — OPM fell to 25.7% in June 2026 from 35.1% in September 2025 — despite stable costs, indicating potential pricing pressure or input cost volatility not yet offset by efficiency gains. 3) PAT growth is increasingly reliant on one-time gains, as operational PAT rose only 9% excluding the asset sale, suggesting underlying business momentum may be weaker than headline numbers imply. 4) The company faces regulatory risks from price controls and cyber security threats, as highlighted in the AGM report, which could impact profitability if unaddressed.

📋 Recent Filings

• Announcement2026-09-25Procter & Gamble Health Ltd announced that its trading window will close on September 25, 2026, preventing directors and designated employees from tra…
• share transfer2026-09-18Procter & Gamble Health Limited informed shareholders that SEBI extended a special window for re-lodging transfer requests of physical shares lodged b…
• 🟡 Board Meeting2026-09-04Procter & Gamble Health Limited announced the re-appointment of Mr. S. Madhavan as Independent Director for five years effective November 15, 2026, fo…
• 🟡 Board Meeting2026-09-03Procter & Gamble Health Limited held its 59th Annual General Meeting on September 3, 2026, via video conference, adopting the audited financial statem…
• 🔴 annual report2026-08-12The filing announces the 59th AGM of Procter & Gamble Health Limited (PGHL) scheduled for September 3, 2026, featuring FY 2025-26 financial highlights…
• 🔴 Corporate Action2026-08-10Procter & Gamble Health Limited revised its Annual General Meeting record date to August 27, 2026, for the 59th AGM on September 3, 2026, with final d…
• 🟡 Board Meeting2026-08-06Procter & Gamble Health Limited announced unaudited financial results for the quarter ended June 30, 2026, approved by its board on August 6, 2026. Th…
• 🔴 Financial Results2026-08-06Procter & Gamble Health Limited reported unaudited Q1 FY2026 results with sales rising 7% YoY to ₹356 crores and PAT up 45% to ₹96 crores, driven by b…
• share transfer2026-07-03Procter & Gamble Health Limited confirmed that securities dematerialized during the quarter ended June 30, 2026 were reported to BSE and NSE within th…
• 🟡 Board Meeting2026-06-26Procter & Gamble Health Limited announced a recommended final dividend of Rs. 45 per equity share for FY 2025-26, subject to shareholder approval at t…

🧠 Analyst's Read

PGHL remains a high-margin, debt-free player with strong returns and consistent shareholder returns, but the recent slowdown in revenue growth and margin pressure, coupled with the absence of new growth catalysts, warrant close scrutiny. Investors should monitor the upcoming AGM on September 3, 2026, for any strategic updates or forward guidance that could rekindle momentum.

Based on filing content and financial data. Not a recommendation.